AU2001256914A1 - Mast cell regulation - Google Patents

Mast cell regulation

Info

Publication number
AU2001256914A1
AU2001256914A1 AU2001256914A AU5691401A AU2001256914A1 AU 2001256914 A1 AU2001256914 A1 AU 2001256914A1 AU 2001256914 A AU2001256914 A AU 2001256914A AU 5691401 A AU5691401 A AU 5691401A AU 2001256914 A1 AU2001256914 A1 AU 2001256914A1
Authority
AU
Australia
Prior art keywords
mast cell
cell regulation
regulation
mast
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001256914A
Inventor
Gunnar Nilsson
Zou Xiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoventus Project AB
Original Assignee
INNOVENTUS UPPSALA LIFE SCIENC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNOVENTUS UPPSALA LIFE SCIENC filed Critical INNOVENTUS UPPSALA LIFE SCIENC
Publication of AU2001256914A1 publication Critical patent/AU2001256914A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001256914A 2000-05-08 2001-05-08 Mast cell regulation Abandoned AU2001256914A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/566,787 2000-05-08
US09/566,787 US6465187B1 (en) 2000-05-08 2000-05-08 Method of treatment
PCT/SE2001/000994 WO2001085096A2 (en) 2000-05-08 2001-05-08 Mast cell regulation

Publications (1)

Publication Number Publication Date
AU2001256914A1 true AU2001256914A1 (en) 2001-11-20

Family

ID=24264373

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001256914A Abandoned AU2001256914A1 (en) 2000-05-08 2001-05-08 Mast cell regulation

Country Status (5)

Country Link
US (1) US6465187B1 (en)
EP (1) EP1280547A2 (en)
JP (1) JP2003534255A (en)
AU (1) AU2001256914A1 (en)
WO (1) WO2001085096A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100586428C (en) * 2001-11-02 2010-02-03 加州大学校务委员会 Compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection and application thereof in preparing medicine
WO2012004800A1 (en) 2010-07-08 2012-01-12 Ramot At Tel-Aviv University Ltd. Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
EP3737757A4 (en) * 2018-01-12 2021-09-22 Children's Hospital Medical Center Methods of treatment by inhibition of bfl 1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
KR960034413A (en) 1995-03-24 1996-10-22 권계홍 Apoptosis regulatory genes
US6472170B1 (en) * 1996-08-02 2002-10-29 Dana-Farber Cancer Institute BCL-Xy, a novel BCL-X isoform, and uses related thereto
NZ507426A (en) * 1998-05-18 2003-08-29 Apoptosis Technology Inc Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
CA2338328A1 (en) * 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression

Also Published As

Publication number Publication date
EP1280547A2 (en) 2003-02-05
JP2003534255A (en) 2003-11-18
WO2001085096A3 (en) 2002-06-20
US6465187B1 (en) 2002-10-15
WO2001085096A2 (en) 2001-11-15
WO2001085096A9 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
AU2001252014A1 (en) Photovoltaic cell
AU2002368042A1 (en) Photovoltaic cell
AU2002340079A1 (en) Electrochemical cell
AU5268001A (en) Fuel cell
AU2001243525A1 (en) Battery
AU2001292317A1 (en) Fuel cell
AU2001252015A1 (en) Photovoltaic cell
AU2001278753A1 (en) Air-hydrogen cell
AUPR636401A0 (en) Fuel cell stack configuration
AU2002360007A1 (en) Fuel cell
AU5833701A (en) Improved electrolytic cell
AU2002230861A1 (en) Multi-axis load cell
AU2035601A (en) Load cell
AU2001283193A1 (en) Battery cathode
AU2001287064A1 (en) Battery
AU2001245493A1 (en) Tower structure
AU2002304886A1 (en) Fuel cell
AU2002349713A1 (en) Nickel-hydrogen cell
AU2001267724A1 (en) Electrochemical cell
AU2001257429A1 (en) Battery
AU2001257430A1 (en) Battery
AU2002213329A1 (en) Battery
AU2001269081A1 (en) Electrochemical cells
EP1148579A3 (en) Mast assembly
AU2002249072A1 (en) Electrochemical cell stack